Download PDF
Review  |  Open Access  |  22 Jun 2022

Current status of the treatment of paragonimiasis

Views: 1686 |  Downloads: 859 |  Cited:   3
One Health Implement Res 2022;2:96-107.
10.20517/ohir.2022.10 |  © The Author(s) 2022.
Author Information
Article Notes
Cite This Article


Paragonimiasis, a foodborne trematodiasis is caused by various Paragonimus species endemic in Asia, Africa, and the Americas. Human infection occurs through consuming improperly cooked freshwater crustaceans, crabs or crayfish, eating raw meat of paratenic hosts or by ingesting metacercariae from contaminated hands and cooking utensils. More than 292 million persons worldwide are at risk. The morbidity associated with paragonimiasis includes acute febrile illness and chronic pleuro-pulmonary manifestations which may be confounded with tuberculosis or lung cancer. Ectopic manifestations mostly involve the central nervous system, heart, or subcutaneous tissues. Objectives: to evaluate the efficacy and safety of currently available drugs praziquantel (PZQ) and triclabendazole (TCZ). Methods: a PubMed and Google Scholar search and reference selection was performed according to the the Preferred Reporting Items for Systematic Reviews protocol using a combination of the terms “paragonimiasis” AND “treatment” OR “therap*” from 01/2000 to 02/2022. Results: no randomized controlled trials were identified. Five open trials on 487 patients treated with PZQ showed 81%-100% parasite clearance depending on dosage and duration. Three open trials on 226 patients with TCZ showed a 99.6% efficacy. A quantitative comparison was not applicable to retrospective analyses of hospital records, case series and case reports because of surgical interventions, various co-morbidities and -medications and definitions of cure. Some patients treated with PZQ required multiple courses or re-treatment with TCZ, whereas one patient treated with TCZ required re-treatment with PZQ. Conclusions: PZQ and TCZ are usually effective for treating paragonimiasis. Controlled randomized trials are required to compare the safety, efficacy and applicability of PZQ versus TCZ and to evaluate combined PZQ-TCZ therapy.


Paragonimus, paragonimiasis, lung fluke, praziquantel, triclabendazole


Paragonimiasis belongs to the family of foodborne trematodiases and is a neglected tropical disease. Paragonimiasis is caused by various species of the genus Paragonimus. Out of the 50 different species isolated from freshwater crabs or crayfish in Asia, Africa and the Americas, a dozen species are known to cause disease in humans[1].

Human infection occurs through consuming improperly cooked freshwater crustaceans, crabs or crayfish, eating paratenic hosts such as wild boar and deer or by ingesting metacercariae from contaminated hands and cooking utensils[2,3]. Metacercariae may also be present in raw juice extracted from crabs/crayfish. Traditionally, in Korea and Japan the juice is used as traditional medicine for humans and in some African societies raw crabs are thought to increase fertility[2].

In subtropical and tropical countries paragonimiasis occurs especially in marginalized populations. In Africa and in the Americas, the disease is frequently associated with a low standard of living and insufficient or irregular food supply, causing people to catch and eat freshwater crabs. In Asia, raw or undercooked crabs are regarded as a delicacy including “drunken crab” in China, “Kung Ten” and “Nam Prik Poo” in Thailand, “Ke Jang” in Korea and “Kinilao” and “Sinugba” in the Philippines[2].

By consequence, paragonimiasis is expected to occur in settings where people do not have sufficiently to eat and/or where people consider eating raw crabs/crayfish as a delicacy. Other risks to take into account include eating undercooked paratenic host meat and traditional beliefs about eating raw crab meat or juice[2,3].

Approximately one million people are infected every year. Human infections have been reported from 39 countries and areas, although the major endemic areas are in Asia. More than 20 million persons are infected and 292.8 million persons are at risk[4,5]. Paragonimiasis has always been a serious medical problem in some countries, such as China, Japan, Korea, the Philippines, Cameroon; Nigeria and Ecuador[5,6]. The number of patients decreased in Japan and Korea over the last decades. In the meantime, new endemic foci have emerged, raising the necessity for effective treatment[6,7].

The morbidity associated with paragonimiasis is directly related to the development of ingested metacercariae in the final host. Metacercariae released from ingested crabC flesh develop into juvenile worms which penetrate the intestinal wall and then follow a complex migration route through the peritoneum, the diaphragm and the pleura to finally reach the lung parenchyma. Typically, adult flukes encapsulate within the pleura or in the lung parenchyma. In the former case pleuritis or pleural thickening will develop. In the latter case eggs are released into bronchioles, coughed up, mixed with sputum, and are either expectorated or swallowed for later excretion via feces. The clinical picture (cough, hemophthysis, fever, asthenia, pleura effusions, pulmonary masses, lung cavernae) is very similar to tuberculosis (TB)[8]. Therefore, paragonimiasis in Vietnam is also called “eosinophilic TB” (Richter 2002, personal observation, unpublished). In endemic areas paragonimiasis may also be associated with TB or it may be confused with lung cancer[8-10].

Symptoms of pulmonary paragonimiasis are results of pleuritis and pneumonia/bronchitis. Pleuritis is caused by worms present in the pleural cavity inducing pleural effusion with massive eosinophil infiltration[11].

Extrapulmonary localization occurs in about 1% of all patients, its frequency depending on the Paragonimus species[1]. The most frequent ectopic localization is in the brain with 30%-60% of all extrapulmonary localizations[1]. Other ectopic localization are: spinal cord, eyes, subcutaneous tissues, heart muscles, mediastinum, breast, bone marrow, liver, spleen, pleural cavity and pericardial cavity and scrotum[1]. Globally, the disability weight of paragonimiasis is high[12].

This review aims to provide an update on how to treat paragonimiasis with either triclabendazole or praziquantel, the two drugs currently available.


This study is reported according to the Preferred Reporting Items for Systematic Reviews[13].

The PUBMED database was searched using a combination of the terms “paragonimiasis” AND “treatment*” OR “therap*” from 01/2000 to 02/2022. Since a tentative search did not show any randomized controlled trial (RCT), in the final search, open clinical trials, case reports, case series and retrospective analyses of hospital records were looked for as well.

Additional searches were undertaken in Google Scholar, and reference lists of included papers were manually searched. After duplicates were removed, the titles and abstracts of the records were screened for relevance and the full-text articles were reviewed for eligibility. Due to the small number of publications on the topic, all publications describing at least one case of paragonimiasis treated with praziquantel or triclabendazole were included regardless of study population, intervention type, outcome measures, and duration of follow-up. The non-RCT studies were analyzed and summarized to provide a comprehensive profile on the treatment of paragonimiasis.

Data extraction and analysis

Data extracted included study origin, type of study, study inclusion and exclusion criteria, patient characteristics, disease diagnoses, treatment details, study outcome measures, and results. All analyses that were made are summarized in Tables 1-3 and narratively described in the text.

Table 1

Open clinical trials with praziquantel

Country/regionParagonimus speciesOrgan affectedStudy designNumber of patientsDosage
Outcome measureOutcomeReference
South KoreaP. westermaniLungsOpen trial
Comparing 3 doses of praziquantel
523 × 25 for 1 day
3 × 25 for 2 days
3 × 25 for 3 days
Presence of eggs in sputum, disappearance of haemoptysis; regression/disappearance of radiological findingsNo eggs in sputum after 3 × 25 mg/kg/d for 3 days independent of the intensity of paragonimiasis; almost all patients improved clinically. In all cases X-ray was normal after 1 year;
3 × 25 mg/kg single dose, 3 × 25 mg/kg/d for 2 days less effective
ChinaP. westermaniLungsOpen trial
Comparing 3 doses of praziquantel
403 × 20 for 2 days
2 × 15 for 5 days
3 × 25 for 3 days
Presence of eggs in sputumIn 91% of patients no eggs detected 90 days after treatment with 3 × 35 mg/kg/d for 3 days
3 × 20 mg/kg/d for 2 days,
2 × 15 mg/kg/d for 5 days less effective
EcuadorP. mexicanusLungsOpen trial
Comparing 2 doses of praziquantel
433 × 25 for 1 day
3 × 25 for 2 days
Decrease of IgG- and IgE-antibodiesIgE-antibodies decreased more rapidly than IgG-antibodies [16]
NigeriaP. utero-bilaterialisLungsOpen trial
Comparing 3 doses of praziquantel
3223 × 15 for 2 days
3 × 20 for 2 days
3 × 25 for 2 days
Presence of eggs in sputumIn 87% no eggs detected after 3 × 25 mg/kg/d for 1 day
3 × 15 mg/kg/d and 3 × 20 mg/kg/d for 2 days were less effective; cure rate seemed to be higher in children and young adults
CameroonP. africanusLungsOpen trial303 × 25 for 3 daysPresence of eggs in sputum; symptoms and signs; regression/disappearance of radiological findingsAbsence of eggs in sputum, disappearance of symptoms and signs in all patients 2 months after treatment; partial regression of radiological findings [18]
Table 2

Clinical trials with triclabendazole

Paragonimus speciesOrgan affectedStudy designNumber of patientsDosage
Outcome measureOutcomeReference
Amazon region
P. mexicanusLungsClinical trial using praziquantel as “therapeutic control”
5 single dose
for 3 days
Praziquantel (3 × 25 for 3 days)
Presence of eggs in sputum; disappearance of symptoms + signsComplete recovery in all patients; eggs were cleared from sputum more rapidly with 3 doses of triclabendazole; no difference between triclabendazole and praziquantel [19]
EcuadorP. mexicanusLungsOpen clinical trial
Comparing 2 doses of triclabendazole
2 × 10 on one day
Presence of eggs in sputum; disappearance of symptoms + signs; regression/disappearance of radiological findingsEggs were cleared from sputum in all patients (disappearance occurred more rapidly with 2 × 10 mg/kg); symptoms + signs regressed in 10% to 35% of patients; radiological findings diminished in size, but remained visible in up to 83% [20]
CameroonP. utero-bilateralisLungsOpen clinical trial1010 single dosePresence of eggs in sputum; disappearance of symptoms + signsIn 9/10 patients eggs were cleared from sputum 11 months after treatment; 7/10 patients fully recovered [21]
Table 3

Retrospective analysis of hospital records, case series and case reports

Origin of patientsType of studyNumber of patients
(age years)
Paragonimus speciesAffected organs/concomitant diseaseTreatment
TCZ = triclabendazole
PZQ = praziquantel
ChinaCase report4
P. skrjabiniLungs, pleural cavity, brain, subcutaneous tissueTCZ10 for 3 daysRecovery [22]
ChinaRetrospective analysis of hospital records94
P. westermaniLungs, pleural cavity, brain, liver, subcutaneous tissue PZQ150-250 for 2-3 daysaImprovement/recoveryb [23]
ChinaCase report5
P. skrjabiniLungsTCZ10 for 3 daysRecovery [24]
ChinaRetrospective analysis of hospital records89
P. not specifiedBrainPZQ
(72 patients)
Dosage not specified? [25]
ChinaRetrospective analysis of hospital records27
P. westermani or P. skrjabiniBrainPZQ3 × 25 for 3 daysImprovement/recoveryc [26]
ChinaCase report1
P. not specifiedLungs/pleural effusionPZQ3 × 50 for 3 days; 2 further courses during 12 monthsRecovery [27]
ChinaRetrospective analysis of hospital records123
P. not specifiedLungs/pleural effusion; tuberculosisPZQ3 × 25 for 3 daysdImprovement/recovery [28]
ChinaCase reports2
(21, 27)
P. skrjabiniScrotumPZQ3 × 25 for 3 days Recovery [29]
ChinaCase report1
P. not specifiedintra-orbital, brainPZQ + corticosteroidseDosage not specifiedRecovery [30]
China Retrospective analysis of hospital records57
P. skrjabini Pericardial effusion/pericardial tamponade PZQf3 × 25 for 3 days;
1-3 repetitionsg
Improvement [31]
ChinaCase report3
P. skrjabiniBrainPZQ3 × 25 for 3 days, 1-2 repetitionsRecovery [32]
ChinaRetrospective analysis of hospital records8
P. heterotremusLungsPZQ
3 × 25 for 3 daysRecovery [9]
ChinaRetrospective analysis of hospital records11
P. not specifiedLungs, pleural effusion, brain, liver PZQ
followed by TCZ
3 × 25 for 3 days;
1-2 repetitionsh
8 patients recovered; 3 improved [33]
JapanCase report1
P. miyazakiiLungsPZQ3 × 25 for 3 daysRecovery [34]
JapanCase report1
P. miyazakiiPleural cavity/pleural effusionPZQ3 × 25 for 3 daysRecovery [35]
JapanCase report1
P. westermaniLungsPZQ3 × 25 for 3 daysImprovement [36]
JapanCase report1
P. westermaniLungs/familial mediterranean feverPZQ3 × 25 for 3 daysImprovement [37]
JapanCase report1
P. westermaniLungs/pleural effusionPZQ3 × 25 on 1 dayImprovement [38]
JapanCase report1
P. westermaniPleural cavityPZQ3 × 25 for 3 daysRecovery [39]
South KoreaRetrospective analysis of hospital records32
P. westermaniLungs/pleural effusionPZQ3 × 25 for 3 daysRecovery in all patients after 2-3 courses [11]
South KoreaCase report1
P. westermaniLungs, pleural cavity/pleural effusionTCZ; followed by PZQi10 single dose (3 × 25)TCZ no effect
Recovery after PZQ
TaiwanCase report1
P. westermaniColonPZQ3 × 25 for 2 daysRecovery [41]
MalaysiaCase report1
P. not specifiedLungsPZQ3 × 25 for 2 daysRecovery [42]
Thailand Case report1
P. heterotremus
Lungs/tuberculosisPZQ3 × 25 for 3 daysRecovery [43]
NepalCase report1
P. westermaniLungsPZQ3 × 25 for 3 daysRecovery [44]
NepalCase report1
P. not specifiedPericardium/pericardial tamponadePZQ3 × 25 for 3 daysRecovery [45]
EcuadorRetrospective analysis of hospital records45
P. mexicanusLungsPZQ3 × 17.5 for 3 daysRecovery [46]
EcuadorCase report3
P. mexicanusLungsTCZ5 for 3 daysRecovery [47]
EcuadorCase series?P. mexicanusLungsPZQ3 × 2595%-100% [7]
EcuadorCase report1
P. mexicanusLungsPZQ3 × 25 for 3 daysImprovement [46]
ColumbiaCase series24
P. mexicanusLungsPZQ3 × 25 for 3 daysRecovery [48]
PeruCase report1
P. mexicanusLungsTCZ2 × 10 on
2 subsequent days
Improvement [49]
USACase series9
P. kellicottiLungsPZQ3 × 25 for 2-3 daysRecovery [50]
USACase report1
P. kellicottiLung/pleural effusionPZQ3 × 25 for 2 daysImprovement [51]
USACase report1
P. kellicottiLungsPZQ3 × 25 for 4 daysRecovery [52]
USACase report1
P. westermaniLungsPZQ3 × 25 for 3 daysRecovery [10]


No randomized controlled trials were identified. Therefore, open clinical trials, retrospective analyses of hospital records, cases series and case reports were analyzed. The open trials with praziquantel are summarized in Table 1. All trials were performed between 1981 and 1989, a couple of years after the introduction of praziquantel into the market. The five studies on 487 patients aimed to identify the optimal dosage for paragonimiasis in the lungs. Most studies performed in South Korea and China showed that in 81%-100% of patients treated with 3 × 25 mg/kg/d for three days no eggs were detected in sputum after three months[14,15]. Lower doses, such as 3 × 20 mg/kg/d for 2 days, were less effective. Radiological findings, such as cavities, nodular opacities, pleural effusion diminished in size, but remained visible after 90 days post-treatment[15]. According to Rim et al., all patients improved clinically, and radiological findings reversed to normal after one year[14].

The efficacy of the treatment with praziquantel did not seem to depend on the Paragonimus species.

In three open trials on 226 patients triclabendazole was used [Table 2]. The two studies performed in Ecuador were designed to identify the optimal dosage. 5 mg/kg/day for three days cleared eggs from the sputum more rapidly than 5 mg/kg/d in a single dose. Similarly, 2 × 10 mg/kg on one day cleared eggs from the sputum more rapidly than 10 mg/kg in a single dose [Table 2][19,20]. Calvopiña et al. reported a similar efficacy of triclabendazole (5 mg/kg/d for 2 days) and praziquantel (3 × 25 mg/kg/d for 3 days). However, the study was not designed to allow a comparison of the efficacy of both drugs[19].

Retrospective analyses of hospital records, case series and case reports is shown in Table 3. Of the 558 cases described, 425 were from China, 52 from Ecuador, 33 from South Korea, 24 from Columbia and 12 from the USA. From the remaining countries, only single cases were reported. Since the great majority of patients were from Asia, the dominant parasite species was P. westermani in 160 cases, followed by P. skrjabini (71 cases) and P. heterotremus (9 cases). On the American continent, patients were infected with P. mexicanus (74 cases) or P. kellicotti (12 cases). The great majority of the patients had paragonimiasis of the lungs and/or the pleural cavity. In Chinese patients the brain, the pericardium and the liver were also affected.

544 cases were treated with praziquantel and 14 cases with triclabendazole. Usually, praziquantel was administered in a dose of 3 × 25 mg/kg/d for three days and triclabendazole in a dose of 10 mg/kg/d for one or two days. Since the definition of improvement and cure varied greatly between the studies, a quantitative comparison of the efficacy of the different treatments was not possible. To indicate the outcome of the treatment in a narrative manner, the terms “improvement” and “recovery” were therefore used.

After treatment with praziquantel (3 × 25 mg/kg/d) recovery was reported in 147 cases and improvement in 66 cases. In the 244 cases from the retrospective analysis of hospital records either improvement or recovery were noted. In a substantial number of patients full recovery needed additional treatment courses with praziquantel.

All cases of paragonimiasis caused by P. mexicanus (Ecuador, Columbia) and P. kellicotti (USA) were cured after praziquantel (3 × 25 mg/kg/d) except for a single case with a chronic disease[7,10,48,50-52]. In 9 patients infected with P. skrjabini and treated with triclabendazole recovery was reported[24].

Since the patients differed regarding to organ manifestation, disease duration, stage and severity, co-morbidity (such as TB) and other host-related factors, no conclusion can be drawn on the efficacy of praziquantel for the treatment of paragonimiasis in general. Particularly, it is impossible to determine the efficacy of praziquantel in the treatment of brain paragonimiasis. Many patients were operated and/or received additional medications such as methylprednisolone or anti-epileptics. Two larger case series with cerebral paragonimiasis from China, however, indicate that the great majority of patients improved[25,26].

Two case reports merit to be discussed in detail. Qian et al. reported that in some patients with paragonimiasis in the brain multiple courses of praziquantel (3 × 25 mg/kg/d for 3 days) did not result in improvement[33]. These patients were cured after an additional treatment with 10 mg/kg triclabendazole. In contrast, Kyung et al. observed no effect of triclabendazole as the primary treatment of a patient with lung paragonimiasis. The patient was cured after treatment with praziquantel[40].

None of the studies was designed to allow the comparison of the efficacy of praziquantel and triclabendazole.


Paragonimus species develop in a broad range of specific snail (= first intermediate host) and crab/crayfish species (= second intermediate hosts). The final host encompasses many different species of wild and domestic mammals which consume freshwater crabs/crayfish, such as mink bobcat, raccoon, civet, coyote, fox, dog, skunk, weasel, badger, marten, boar, pig, deer, guinea pig, tiger, leopard, panther, and cat[1-4]. Since paragonimiasis is a zoonosis with many animal reservoirs it is impossible to eradicate, and new cases will continue to occur as long as people consume fresh/undercooked crab/crayfish. Early diagnosis and effective treatment are therefore the mainstay to avoid the development of debilitating, and in the case of brain paragonimiasis, life-threatening disease.

In the open clinical trials, praziquantel (3 × 25 mg/kg/d for 3 days) cleared eggs from the sputum taken 90 days post-treatment in all patients with pulmonary paragonimiasis[14,15]. Symptoms and signs disappeared, and radiological findings reversed to normal after one year[14]. However, it cannot be excluded that the true cure-rate was lower: The sensitivity of the detection of eggs in sputum is not known, the method has never been standardized, and day-to-day-variation of release of eggs into the bronchi may have an impact on the diagnostic precision of the method.

In the open clinical trials with triclabendazole, it was shown that 5 mg/kg/d were needed to rapidly clear eggs from the sputum[19,20]. None of the studies allowed to compare the efficacy of praziquantel with that of triclabendazole. Of the 558 cases identified in retrospective analyses of hospital records, case series and case reports, 544 were treated with praziquantel and only 14 with triclabendazole. Since 2003 only a few cases treated with triclabendazole have been reported.

After treatment with praziquantel (3 × 25 mg/kg/d) recovery was reported from 147 patients and improvement from 66 patients. In the 244 cases from the retrospective analysis of hospital records either improvement or recovery were noted. Similar results were reported also in case series and case reports on patients published earlier than 2000[17,53-67] In 9 patients infected with P. skrjabini and treated with triclabendazole and recovery was reported. Since the patients differed with regard to organ manifestation, disease duration, stage and severity, co-morbidity (such as tuberculosis), other therapeutic interventions such as surgery and other host-related factors, no conclusion can be drawn on the efficacy of praziquantel compared to that of triclabendazole. For instance, in areas where tuberculosis and paragonimiasis overlap and patients are treated with antibiotics for long periods, the efficacy of the treatment of paragonimiasis may be impaired[46]. Rifampicin, for example, induces degrading enzymes and thereby reduces the plasma level of praziquantel to zero[8].

In 11 patients with cerebral paragonimiasis multiple courses of praziquantel (3 × 25 mg/kg/d for 3 days) did not result in improvementl[33]. These patients were cured after an additional treatment with 10 mg/kg triclabendazole. In a report of a case with lung paragonimiasis, the treatment with triclabendazole remained without effect. The patient was cured after treatment with praziquantel[40]. Whether these findings indicate that in the first case praziquantel, and in the second case triclabendazole was not sufficiently absorbed or rapidly degraded, remains to be elucidated. The findings, however, underline that the characteristic pharmacokinetics of praziquantel and triclabendazole have to be understood to guarantee that the medication is effective[68].

Since schistosomiasis and paragonimiasis overlap in many countries in Africa and Asia, and because praziquantel is administered to school-age children as preventive mass chemotherapy in all schistosomiasis-endemic areas, it has been suggested that the regular treatment with praziquantel may have an additional benefit on the incidence of paragonimiasis in children and adolescents[69].

However, experimental studies show that a 10-fold higher concentration of praziquantel is required to paralyze the small liver fluke Clonorchis sinensis, another member of the family of food-borne trematodes, than to paralyze Schistosoma mansoni[4].

On the other hand, in areas endemic for Taenia (T.) solium infection and possible unrecognized cerebral cysticercosis, the activity of praziquantel against T. solium metacestodes and the consequent immune response could possibly cause cerebral edema and epilectic attacks which is not expected for triclabendazole which is apparently not active on cysticerca[70,71]. Furthermore, TCZ is not only active against small liver flukes but also against the large liver fluke Fasciola hepatica[68,21,44,72]. Although TCZ is a well investigated and safe drug higher daily TCZ dosages and co-medication of PZQ and TCZ of unresponsive cases has apparently never been tried.


Both, PZQ and TCZ are usually effective for treating paragonimiasis. In some cases not responding to one of the drugs, the other has proven effective, so far. Either drug has its advantages depending on the clinical and epidemiological context. PZQ is effective against a large range of plathelminthes including schistosomes, small liver flukes and taeniae. This effect can be advantageous in areas where these infections are co-endemic. TCZ has the advantage of requiring lower dosages and fewer treatment courses, being effective also against Fasciola spp. as well as apparently not being active on unrecognized cysticercosis co-infection, which might pose problems in areas where Taenia solium is co-endemic. For comparison of the efficacy of PZQ versus TCZ double blinded, controlled randomized investigations are required. Furthermore, trials are warranted to find out the ideal medication (single dose versus multiple dose-therapy schemes, TCZ-PZQ combination-therapy for a given setting taking into account co-infections and logistic issues.


Author’s contribution

The author solely contributed this article.

Availability of data and materials

Not applicable.

Financial support and sponsorship

The author has received praziquantel and financial support for a clinical study on schistosomiasis from Merck do Brasil in 1988-1989 and from Ciba Geigy for a clinical study on triclabendazole in fascioliasis in 1995.

Conflicts of interest

The author declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.


© The Author(s) 2022.


1. Chai J. Paragonimiasis. Handb Clin Neurol 2013;114:283-96.

2. Garcia LS, Procop GW. Diagnostic medical parasitology 2016. pp. 507-8.

3. Banzai A, Sugiyama H, Hasegawa M, Morishima Y, Kawakami Y. Paragonimus westermani metacercariae in two freshwater crab species in Kagoshima Prefecture, Japan, as a possible source of infection in wild boars and sika deer. J Vet Med Sci 2021;83:412-8.

4. Health Organization Study Group. Control of foodborne trematode infections. World Health Organ Tech Rep Ser 1995:849;1-157.

5. Keiser J, Utzinger J. Emerging foodborne trematodiasis. Emerg Infect Dis 2005;11:1507-14.

6. Yoshida A, Doanh PN, Maruyama H. Paragonimus and paragonimiasis in Asia: An update. Acta Trop 2019;199:105074.

7. Calvopiña M, Romero D, Castañeda B, Hashiguchi Y, Sugiyama H. Current status of Paragonimus and paragonimiasis in Ecuador. Mem Inst Oswaldo Cruz 2014;109:849-55.

8. Sharma DC. Paragonimiasis causing diagnostic confusion with tuberculosis. Lancet Infect Dis 2005;5:538.

9. Shu QH, Yang Y, Li SD, et al. Analysis of the misdiagnosis of 8 adult cases of paragonimiasis with lung masses as the main manifestation in Xishuangbanna, Yunnan. J Cardiothorac Surg 2021;16:28.

10. Parikh MS, Seeley E, Krishna G. Electromagnetic navigational bronchoscopy spares a drunken crab from the surgeon’s knife. J Bronchology Interv Pulmonol 2017;24:241-3.

11. Oh IJ, Kim YI, Chi SY, et al. Can pleuropulmonary paragonimiasis be cured by only the 1st set of chemotherapy? Intern Med 2011;50:1365-70.

12. Feng Y, Fürst T, Liu L, Yang GJ. Estimation of disability weight for paragonimiasis: a systematic analysis. Infect Dis Poverty 2018;7:110.

13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

14. Rim HJ, Chang YS, Lee JS, Joo KH, Suh WH, Tsuji M. Clinical Evaluation Of Praziquantel(Embay 8440; Biltricide(R)) In The Treatment Of Paragonimus Westermani. Kisaengchunghak Chapchi 1981;19:27-37.

15. Cao WJ, He LY, Zhong HL, Xu ZS, Bi YC, et al. Paragonimiasis: treatment with praziquantel in 40 human cases and in 1 cat. Arzneimittelforschung 1984;34:1203-4.

16. Knobloch J, Paz G, Feldmeier H, Wegner D, Voelker J. Serum antibody levels in human paragonimiasis before and after therapy with praziquantel. T Roy Soc Trop Med H 1984;78:835-6.

17. Udonsi JK. Clinical field trials of praziquantel in pulmonary paragonimiasis due to Paragonimus uterobilateralis in endemic populations of the Igwun Basin, Nigeria. Trop Med Parasitol 1989;40:65-8.

18. Moyou-Somo R, Tagni-Zukam D. [Paragonimiasis in Cameroon: clinicoradiologic features and treatment outcome]. Med Trop (Mars) 2003;63:163-7.

19. Calvopiña M, Guderian RH, Paredes W, Chico M, Cooper PJ. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. T Roy Soc Trop Med H 1998;92:566-9.

20. Calvopiña H, Guderian RH, Paredes WY, J. Cooper P. Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis. T Roy Soc Trop Med H 2003;97:451-4.

21. Ripert C, Couprie B, Moyou R, Gaillard F, Appriou M, Tribouley-duret J. Therapeutic effect of triclabendazole in patients with paragonimiasis in Cameroon: a pilot study. T Roy Soc Trop Med H 1992;86:417.

22. Hu P, Liu YH. [A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2001;19:305-7.

23. Ming-gang C, Zheng-shan C, Xiang-yuan S, Ming-da L, Blair D, et al. Paragonimiasis in Yongjia County, Zhejiang Province, China: clinical, parasitological and karyotypic studies on Paragonimus westermani. Southeast Asian J Trop Med Public Health 2001;32:760-9.

24. Gao J, Liu Y, Wang X, Hu P. Triclabendazole in the treatment of paragonimiasis skrjabini. Chin Med J (Engl) 2003;116:1683-6.

25. Chen J, Chen Z, Lin J, et al. Cerebral paragonimiasis: a retrospective analysis of 89 cases. Clin Neurol Neurosurg 2013;115:546-51.

26. Xia Y, Ju Y, Chen J, You C. Cerebral paragonimiasis: a retrospective analysis of 27 cases. J Neurosurg Pediatr 2015;15:101-6.

27. Hu Y, Qian J, Yang D, Zheng X. Pleuropulmonary paragonimiasis with migrated lesions cured by multiple therapies. Indian J Pathol Microbiol 2016;59:56-8.

28. Gong Z, Miao R, Shu M, et al. Paragonimiasis in Children in Southwest China: A retrospective case reports review from 2005 to 2016. Medicine (Baltimore) 2017;96:e7265.

29. Liang T, Liang G, Du Y, et al. Scrotal Paragonimiasis in adults: Two case reports and review of literature. Medicine (Baltimore) 2018;97:e0328.

30. Xia Y, Chen J, Chen LY. Intraorbital paragonimus infection. Indian J Ophthalmol 2019;67:1736.

31. Wu Y, Zhou Y, Jin X, et al. Diagnosis and surgical management of pericardial effusion due to paragonimiasis. Int J Infect Dis 2019;83:102-8.

32. Wang Q, Hou L, Liu L. Diagnosis and treatment of hemorrhagic cerebral paragonimiasis: three case reports and literature review. Turk Neurosurg 2020;30:624-8.

33. Qian M, Li F, Zhang Y, Qiao Z, Shi Y, Shen J. A retrospective clinical analysis of pediatric paragonimiasis in a Chinese children’s hospital from 2011 to 2019. Sci Rep 2021;11:2005.

34. Yatera K, Hanaka M, Hanaka T, et al. A rare case of paragonimiasis miyazakii with lung involvement diagnosed 7 years after infection: a case report and literature review. Parasitol Int 2015;64:274-80.

35. Akaba T, Takeyama K, Toriyama M, et al. Pulmonary paragonimiasis: the detection of a worm migration track as a diagnostic clue for uncertain eosinophilic pleural effusion. Intern Med 2016;55:503-6.

36. Itoh N, Tsukahara M, Yamasaki H, Morishima Y, Sugiyama H, Kurai H. Paragonimus westermani infection mimicking recurrent lung cancer: a case report. J Infect Chemother 2016;22:815-8.

37. Nureki SI, Ishii K, Fujisaki H, et al. Familial mediterranean fever with rheumatoid arthritis complicated by pulmonary paragonimiasis. Intern Med 2016;55:2889-92.

38. Harada T, Kawasaki Y, Tsukada A, et al. Bronchodilator reversibility occurring during the acute phase of paragonimiasis westermani infection. Intern Med 2019;58:297-300.

39. Ogata H, Harada E, Moriya S, et al. Pleuropulmonary paragonimiasis with multiple nodules in the pleura. Intern Med 2020;59:1879-81.

40. Kyung SY, Cho YK, Kim YJ, et al. A paragonimiasis patient with allergic reaction to praziquantel and resistance to triclabendazole: successful treatment after desensitization to praziquantel. Korean J Parasitol 2011;49:73-7.

41. Liu CT, Chen YC, Chen TH, Barghouth U, Fan CK. Intestinal paragonimiasis with colonic ulcer and hematochezia in an elderly Taiwanese woman. Korean J Parasitol 2012;50:349-52.

42. Ponnampalavanar S, Kukreja A, Amir A, Mahmud R. First case report of paragonimiasis in a Malaysian man. Trop Biomed 2020;37:24-8.

43. Petborom P, Linasmita P, Kulpraneet M. Coinfection of pulmonary paragonimiasis and pulmonary tuberculosis in Thailand. J Med Assoc Thai 2016;99 Suppl 8:S231-s6.

44. Gaire D, Sharma S, Poudel K, Pant P. Unresolving pneumonia with pleural effusion: pulmonary paragonimiasis. JNMA J Nepal Med Assoc 2017;56:268-70.

45. Sah R, Gupta N, Chatterji P, et al. Case report: paragonimiasis presenting with pericardial tamponade. Am J Trop Med Hyg 2019;101:62-4.

46. Calvopina M, Romero-Alvarez D, Macias R, Sugiyama H. Severe pleuropulmonary paragonimiasis caused by paragonimus mexicanus treated as tuberculosis in Ecuador. Am J Trop Med Hyg 2017;96:97-9.

47. Calvopiña M, Paredes W, Guderian R, Poltera AA. Eficacia del triclabendazole en paragonimiasis pulmonar humana refractaria a la emetina, bithionol y praziquantel. Parasitol día 1993;17:44-6.

48. Vélez IDB, Ortega J, Hurtado MIM, et al. Epidemiology of paragonimiasis in Colombia. T Roy Soc Trop Med H 2000;94:661-3.

49. Agramonte VF, Ormeño Julca AJ, Coveñas Coronado CDP, Polar Córdova V, Belloso Rodríguez JA. [Pulmonary paragonimiasis. Pediatric case report]. Arch Argent Pediatr 2019;117:e659-63.

50. for Disease Control and Prevention (CDC). Human paragonimiasis after eating raw or undercooked crayfish - Missouri, July 2006-September 2010. MMWR. Morb Mortal Wkly Rep 2010;59:1573-6.

51. Johannesen E, Nguyen V. Paragonimus kellicotti: a lung infection in our own backyard. Case Rep Pathol 2016;2016:2107372.

52. Horn CB, Patel NR, Hawasli JA, Edwards MA. Paragonimus kellicotti presenting with hemoptysis and a left upper lobe mass. Ann Thorac Surg 2016;102:e393-5.

53. A [Endemic pulmonary paragonimiasis in Lower Mundani (Fontem district of southwest Cameroon). Results of treatment with praziquantel]. Bull Soc Pathol Exot 1985;78:334-41.

54. Li R. [Clinical observation of treating 44 cases of paragonimiasis (Paragonimus westermani) with praziquantel (Author’s transl)]. Zhonghua Nei Ke Za Zhi 1982;21:37-8.

55. Cui J, Wang Z, Wu F, Jin X. An outbreak of paragonimiosis in Zhengzhou city, China. Acta Tropica 1998;70:211-6.

56. Vanijanonta S, Radomyos P, Bunnag D, Harinasuta T. Pulmonary paragonimiasis with expectoration of worms: a case report. Southeast Asian J Trop Med Public Health 1981;12:104-6.

57. Johnson RJ, Johnson JR. Paragonimiasis in Indochinese refugees. Roentgenographic findings with clinical correlations. Am Rev Respir Dis 1983;128:534-8.

58. Mariano EG, Borja SR, Vruno MJ. A human infection with paragonimus kellicotti (lung fluke) in the United States. Am J Clin Pathol 1986;86:685-7.

59. Knöll P, Perlewitz J. [Differential diagnosis of paragonimiasis in relation to tuberculosis of the lung by transthoracic needle biopsy]. Z Erkr Atmungsorgane 1986;167:152-7.

60. Añaños G, Trilla A, Graus F, Mas J, Corachán M, Soriano E. [Paragonimiasis and pulmonary tuberculosis]. Med Clin (Barc) 1992;98:257-9.

61. Itakura M, Shinozaki T, Shingyouji M. [A case of Paragonimus Miyazaki with pleuritis and meningoencephalitis]. Nihon Kyobu Shikkan Gakkai Zasshi 1997;35:980-4.

62. Doutsu Y, Taniguchi H, Ashitani J, et al. [A case of paragonimiasis westermani diagnosed on the observation of parasitic ova in bronchial washing fluid and successfully treated with praziquantel]. Kansenshogaku Zasshi 1993;67:491-5.

63. Kaneki T, Kubo K, Tanaka N, et al. [A case of paragonimiasis westermani]. Nihon Kokyuki Gakkai Zasshi 1998;36:623-6.

64. Guiard-Schmid JB, Lacombe K, Osman D, et al. [Paragonimiasis: a rare little known disease]. Presse Med 1998;27:1835-7.

65. Kojima T, Takase K, Kasakura N. [Paragonimiasis Miyazakii with variable X-ray shadows]. Nihon Kokyuki Gakkai Zasshi 1999;37:710-4.

66. Aka NA, Allabi AC, Dreyfuss G, et al. [Epidemiological observations on the first case of human paragonimiasis and potential intermediate hosts of Paragonimus sp. in Benin]. Bull Soc Pathol Exot 1999;92:191-4.

67. Jeong MG, Yu JS, Kim KW, et al. Retroperitoneal paragonimiasis: a case of ectopic paragonimiasis presenting as periureteral masses. J Comput Assist Tomogr 1999;23:696-8.

68. Keiser J, Engels D, Büscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005;14:1513-26.

69. Cumberlidge N, Rollinson D, Vercruysse J, Tchuem Tchuenté LA, Webster B, Clark PF. Paragonimus and paragonimiasis in West and Central Africa: unresolved questions. Parasitology 2018;145:1748-57.

70. M, Gabriël S, Abatih EN, Praet N, Benitez W, Dorny P. Taenia solium human cysticercosis: a systematic review of sero-epidemiological data from endemic zones around the world. PLoS Negl Trop Dis 2015;9:e0003919.

71. Vargas-Calla A, Gomez-Puerta LA, Calcina J, et al. Evaluation of activity of triclabendazole against taenia solium metacestode in naturally infected pigs. Asian Pac J Trop Med 2016;9:23-6.

72. Millán JC, Mull R, Freise S, Richter J. Triclabendazole Study Group. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic fasciola hepatica infection. Am J Trop Med Hyg 2000;63:264-9.

Cite This Article

Export citation file: BibTeX | RIS

OAE Style

Richter J. Current status of the treatment of paragonimiasis. One Health Implement Res 2022;2:96-107.

AMA Style

Richter J. Current status of the treatment of paragonimiasis. One Health & Implementation Research. 2022; 2(4): 96-107.

Chicago/Turabian Style

Joachim Richter. 2022. "Current status of the treatment of paragonimiasis" One Health & Implementation Research. 2, no.4: 96-107.

ACS Style

Richter, J. Current status of the treatment of paragonimiasis. One. Health Implement. Res. 2022, 2, 96-107.

About This Article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (, which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Data & Comments




Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at

Download PDF
Cite This Article 24 clicks
Like This Article 7 likes
Share This Article
Scan the QR code for reading!
See Updates
One Health & Implementation Research
ISSN 2769-6413 (Online)


All published articles are preserved here permanently:


All published articles are preserved here permanently: